Hoffmann-La Roche
Afimkibart
Moderately to Severely Active Ulcerative Colitis
Countdown
207days
Phase 3 readout · Jan 30, 2027
What's at stake
Phase 3 trial results for Afimkibart in Moderately to Severely Active Ulcerative Colitis are due Jan 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06588855: Phase 3 trial, sponsor Hoffmann-La Roche, drug Afimkibart. Primary completion date 2027-01-30 (estimated).”